Chemical Modifications and Design Influence the Potency of Huntingtin Anti-Gene Oligonucleotides
Nucleic Acid Therapeutics · 2023
DOI: 10.1089/nat.2022.0046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2023. Verfasst von Osama Saher und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Karolinska University Hospital, SE-14186 …. Hauptthemen laut MEDLINE: Oligonucleotides, Huntington Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Huntington's disease is a neurodegenerative, trinucleotide repeat (TNR) disorder affecting both males and females. It is caused by an abnormal increase in the length of CAG•CTG TNR in exon 1 of the Huntingtin gene ( HTT ). The resultant, mutant HTT mRNA and protein cause neuronal toxicity, suggesting that reduction of their levels would constitute a promising therapeutic approach. We previously reported a novel strategy in which chemically modified oligonucleotides (ONs) directly target chromosomal DNA. These anti-gene ONs were able to downregulate both HTT mRNA and protein. In this study, various locked nucleic acid (LNA)/DNA mixmer anti-gene ONs were tested to investigate the effects of varying ON length, LNA content, and fatty acid modification on HTT expression. Altering the length did not significantly influence the ON potency, while LNA content was critical for activity. Utilization of palmitoyl-modified LNA monomers enhanced the ON activity relatively to the corresponding nonmodified LNA under serum starvation conditions. Furthermore, the number of palmitoylated LNA monomers and their positioning greatly affected ON potency. In addition, we performed RNA sequencing analysis, which showed that the anti-gene ONs affect the “immune system process, mRNA processing, and neurogenesis.” Furthermore, we observed that for repeat containing genes, there is a higher tendency for antisense off-targeting. Taken together, our findings provide an optimized design of anti-gene ONs that could potentially be developed as DNA-targeting therapeutics for this class of TNR-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Karolinska University Hospital, SE-14186 Huddinge, Sweden.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- Department of Physics, Chemistry and Pharmacy, Biomolecular Nanoscale Engineering Center, University of Southern Denmark, Odense, Denmark.
- Department of Chemistry, Faculty of Science, Benha University, Benha, Egypt.
- Centre for Rare Diseases, Department of Clinical Genetics, Karolinska University Hospital, SE-17176 Stockholm, Sweden.
ORCID-Profile: Osama Saher
Zitieren
APA
Saher, O., Zaghloul, E. M., Umek, T., Hagey, D. W., Mozafari, N., Danielsen, M. B., Gouda, A. S., Lundin, K. E., Jørgensen, P. T., Wengel, J., Smith, C. I. E., & Zain, R. (2023). Chemical Modifications and Design Influence the Potency of Huntingtin Anti-Gene Oligonucleotides. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2022.0046
Vancouver
Saher O, Zaghloul EM, Umek T, Hagey DW, Mozafari N, Danielsen MB, et al. Chemical Modifications and Design Influence the Potency of Huntingtin Anti-Gene Oligonucleotides. Nucleic Acid Therapeutics. 2023. doi:10.1089/nat.2022.0046
BibTeX
@article{Saher2023,
author = {Saher, Osama and Zaghloul, Eman M and Umek, Tea and Hagey, Daniel W and Mozafari, Negin and Danielsen, Mathias B and Gouda, Alaa S and Lundin, Karin E and Jørgensen, Per T and Wengel, Jesper and Smith, C I Edvard and Zain, Rula},
title = {Chemical Modifications and Design Influence the Potency of Huntingtin Anti-Gene Oligonucleotides},
journal = {Nucleic Acid Therapeutics},
year = {2023},
doi = {10.1089/nat.2022.0046}
}
EUVIMED